4.5 Review

Economic Impact of Childhood and Adult Aitention-Deficit/Hyperactivity Disorder in the United States

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jaac.2012.07.008

关键词

ADHD; cost of illness; societal costs; children; adults

资金

  1. Shire Development LLC
  2. Pfizer
  3. Shire
  4. Agency for Health Research and Quality
  5. National Library of Medicine
  6. National Science Foundation
  7. Amgen
  8. Bayer Healthcare
  9. Biogen
  10. Bioscience
  11. Boston Scientific
  12. Covidien
  13. Doichi-Sankyo
  14. EMD Serono
  15. Endo
  16. Medtronic
  17. Merck
  18. Millennium
  19. Novartis
  20. Teva North America

向作者/读者索取更多资源

Objective: Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent mental disorders in children in the United States and often persists into adulthood with associated symptomatology and impairments. This article comprehensively reviews studies reporting ADHD-related incremental (excess) costs for children/adolescents and adults and presents estimates of annual national incremental costs of ADHD. Method: A systematic search for primary United States-based studies published from January 1, 1990 through June 30, 2011 on costs of children/adolescents and adults with ADHD and their family members was conducted. Only studies in which mean annual incremental costs per individual with ADHD above rion-ADHD controls were reported or could be derived were included. Per-person incremental costs were adjusted to 2010 U.S. dollars and converted to annual national incremental costs of ADHD based on 2010 U.S. Census population estimates, ADHD prevalence rates, number of household members, and employment rates by age group. Results: Nineteen studies met the inclusion criteria. Overall national annual incremental costs of ADHD ranged from $143 to $266 billion (B). Most of these costs were incurred by adults ($105B-$194B) compared with children/adolescents ($38B-$72B). For adults, the largest cost category was productivity and income losses ($87B-$138B). For children, the largest cost categories were health care ($21B-$44B) and education ($15B-$25B). Spillover costs borne by the family members of individuals with ADHD were also substantial ($33B-$43B). Conclusion: Despite a wide range in the magnitude of the cost estimates, this study indicates that ADHD has a substantial economic impact in the United States. Implications of these findings and future directions for research are discussed. J. Am. Acad. Child Adolesc. Psychiatry, 2012;51(10):990-1002.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cardiac & Cardiovascular Systems

Clinical Prediction Models for Cardiovascular Disease Tufts Predictive Analytics and Comparative Effectiveness Clinical Prediction Model Database

Benjamin S. Wessler, Lana Y. H. Lai, Whitney Kramer, Michael Cangelosi, Gowri Raman, Jennifer S. Lutz, David M. Kent

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2015)

Article Health Care Sciences & Services

Medicare Is Scrutinizing Evidence More Tightly For National Coverage Determinations

James D. Chambers, Matthew Chenoweth, Michael J. Cangelosi, Junhee Pyo, Joshua T. Cohen, Peter J. Neumann

HEALTH AFFAIRS (2015)

Article Health Care Sciences & Services

Medicare's use of cost-effectiveness analysis for prevention (but not for treatment)

James D. Chambers, Michael J. Cangelosi, Peter J. Neumann

HEALTH POLICY (2015)

Article Health Care Sciences & Services

CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGY

James D. Chambers, Matthew D. Chenoweth, Junhee Pyo, Michael J. Cangelosi, Peter J. Neumann

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2015)

Article Cardiac & Cardiovascular Systems

Clinical Prediction Models for Cardiovascular Disease Tufts Predictive Analytics and Comparative Effectiveness Clinical Prediction Model Database

Benjamin S. Wessler, Lana Y. H. Lai, Whitney Kramer, Michael Cangelosi, Gowri Raman, Jennifer S. Lutz, David M. Kent

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2015)

Review Respiratory System

Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment

Donald R. VanDevanter, Jennifer S. Kahle, Amy K. O'Sullivan, Slaven Sikirica, Paul S. Hodgkins

JOURNAL OF CYSTIC FIBROSIS (2016)

Article Allergy

Indirect comparison of bronchial thermoplasty versus omalizumab for uncontrolled severe asthma

Robert M. Niven, Michael R. Simmonds, Michael J. Cangelosi, Dominic P. Tilden, Suzanne Cottrell, Narinder S. Shargill

JOURNAL OF ASTHMA (2018)

Article Multidisciplinary Sciences

Effect of Treatment Modality on Long-Term Outcomes in Attention-Deficit/Hyperactivity Disorder: A Systematic Review

L. Eugene Arnold, Paul Hodgkins, Herve Caci, Jennifer Kahle, Susan Young

PLOS ONE (2015)

Article Health Care Sciences & Services

Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma

Michael J. Cangelosi, Jesse D. Ortendahl, Lisa M. Meckley, Tanya G. K. Bentley, Ayanna M. Anene, Kelly M. Shriner, John Fox

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2015)

Review Respiratory System

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review

Ranjani Somayaji, Michael D. Parkins, Anand Shah, Stacey L. Martiniano, Michael M. Tunney, Jennifer S. Kahle, Valerie J. Waters, J. Stuart Elborn, Scott C. Bell, Patrick A. Flume, Donald R. VanDevanter

JOURNAL OF CYSTIC FIBROSIS (2019)

Review Biochemistry & Molecular Biology

Sigma-2 Receptors-From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases

Britney N. Lizama, Jennifer Kahle, Susan M. Catalano, Anthony O. Caggiano, Michael Grundman, Mary E. Hamby

Summary: There is a significant medical need to develop disease-modifying treatment options for age-related degenerative diseases of the central nervous system. The sigma-2 receptor plays a role in regulating cell functions and has potential as a therapeutic target for Alzheimer's disease, a-synucleinopathies, and dry age-related macular degeneration.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Gastroenterology & Hepatology

A Cost-Effectiveness Analysis of Exalt Model D Single-Use Duodenoscope Versus Current Duodenoscope Reprocessing Methods

Ananya Das, Michael J. Cangelosi, V. Raman Muthusamy

Summary: The study aimed to estimate the cost-effectiveness of EXALT in the US healthcare system. The results showed that EXALT is a viable and cost-effective strategy for Endoscopic Retrograde Cholangiopancreatography (ERCP), especially with the support of device-specific reimbursement. It can reduce the net costs for hospitals while maintaining QALY gains.

TECHNIQUES AND INNOVATIONS IN GASTROINTESTINAL ENDOSCOPY (2022)

Article Critical Care Medicine

Investing in New Technology in Pulmonary Medicine Navigating the Tortuous Path to Success

Robert Kruklitis, Kim French, Michael Joseph Cangelosi, Kevin L. Kovitz

Article Oncology

Cost Effectiveness of Metal Stents in Relieving Obstructive Jaundice in Patients with Pancreatic Cancer

J. M. Martinez, A. Anene, T. G. K. Bentley, M. J. Cangelosi, L. M. Meckley, J. D. Ortendahl, A. J. Montero

JOURNAL OF GASTROINTESTINAL CANCER (2017)

暂无数据